+2%

est. 2Y upside i

Series D+

Rank

#1988

Sector

Therapeutic Devices

Est. Liquidity

~3Y

Data Quality

Data: Medium

The equity upside over 2 years is limited to ~2% expected return, weighed down by a likely dilutive future round and a preference stack that consumes all value in a bear case.

Last updated: July 19, 2026

Bull (15%)+140%

Synchron achieves FDA approval and signs strategic partnership by end of 2027, leading to acquisition or IPO at 3x current valuation (~$3B). Dilution of 20% reduces net upside to 140%.

Base (55%)+20%

Moderate clinical progress leads to acquisition by a medtech incumbent at ~$1.5B within 2 years. After 20% dilution, common stock yields 20% return.

Bear (30%)-100%

Clinical setbacks, tougher regulatory path, or superior competition from Neuralink causes exit value below $345M. Preferred liquidation preference wipes out common stock entirely.

Est. time to liquidity~3.0 years

Preference Stack Risk

severe

Funding Intensity

3450%

Total funding of $345M represents 34.5% of the $1B valuation; in a sale below $345M, common stock receives nothing.

Dilution Risk

high

As a clinical-stage company with very high capital intensity, Synchron is likely to raise additional capital within 2 years, potentially diluting existing holders by 15-25%.

Secondary Liquidity

limited

Secondary trading is minimal; the secondary implied valuation ($976.65M) is close to the round mark, indicating limited liquidity.

Other — 5 roles

View all 5 open roles at Synchron →

Last updated: February 22, 2026

Questions to Ask at the Interview

Strategic questions based on Synchron's data — designed to show you've done your homework.

  • 1

    “What specific clinical milestones do you expect to achieve in the next 12-18 months, and how do they derisk the technology?”

  • 2

    “How does Synchron's revenue model evolve from clinical trials to commercial sales, and what are the expected unit economics?”

  • 3

    “Given the high preference stack and likely future dilution, how does the company plan to align employee equity incentives with long-term value creation?”

Community

Valuation Sentiment

Our model estimates +2% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.